Immunoexpression of PD-L1 and PD-1 and Its Clinicopathological Correlation in Urothelial Carcinomas
Introduction Urothelial carcinomas are the most common types of bladder tumors that have recently shown a changing trend in treatment protocols with the introduction and approval of immune checkpoint inhibitors. The most important immune checkpoint lies with the PD-1–PD-L1 axis. Although multiple dr...
Guardado en:
Autores principales: | Utpal Kumar, Michael Leonard Anthony, Rishabh Sahai, Ankur Mittal, Prashant Durgapal, Sanjeev Kishore |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Thieme Medical and Scientific Publishers Pvt. Ltd.
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/d188599fd7a040b39142cd9741298b72 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Efficacy and Safety of PD-1 Inhibitor Combined with Anlotinib on Advanced Neuroendocrine Carcinoma
por: YU Xuxu, et al.
Publicado: (2021) -
Adverse Effects and Toxicity of Immune Checkpoint Inhibitors For Patients With Urothelial Carcinoma
por: Di Wang, et al.
Publicado: (2021) -
Treatment-Related Adverse Events with PD-1 or PD-L1 Inhibitors: A Systematic Review and Meta-Analysis
por: Yixi Zhang, et al.
Publicado: (2021) -
Clinicoprognostic and Histopathological Features of Guttate and Plaque Psoriasis Based on PD-1 Expression
por: Chang-Jin Jung, et al.
Publicado: (2021) -
Disease control with prior platinum-based chemotherapy is prognostic for survival in patients with metastatic urothelial cancer treated with atezolizumab in real-world practice
por: Mencinger Marina, et al.
Publicado: (2021)